

DOXYCYCLINE- doxycycline capsule
DOXYCYCLINE HYCLATE- doxycycline hyclate capsule
DOXYCYCLINE HYCLATE- doxycycline hyclate tablet, film coated
Health Department, Oklahoma State

Doxycycline Hyclate

Doxycycline Hyclate 100 mg Warnings Section

The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing use of antibacterial drugs not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. (See ADVERSE REACTIONS.) If severe skin reactions occur, doxycycline should be discontinued immediately and appropriate therapy should be instituted.

Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycycline should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt

ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.


Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

Doxycycline Packaging

STI
DOXYCYCLINE-100 MG CAPSULES
28 COUNT



11 20102228 14555505



STI
EPT-CH
Doxycycline-100MG
14 ct

Doxycycline hyclate
100mg capsules
NDC 141111-0100
L3098811209
Lot: 101111-0100
Ocala, FL 32101
Hartmann



STI
DOXYCYCLINE 100MG
14 COUNT

EXP: 12/04/2026
4286631805
EXP: 12/04/2026

Pharmaceutical Services

Quincy

of Health

of Health



LOT: 30007
EXP: 03/2025

42B

Lotus Co

Chattanooga, TN

37401

Doxycycline

100

mg

20

ct

100

mg

STI
Doxycycline 100MG
20 ct

Doxycycline hyclate

100 MG TABS

LOT: 30007

EXP: 03/2025



SHHR- Doxy (PEP)
Doxycycline 100mg
28 CAP



100% Satisfaction
Guaranteed
1-800-368-6768
www.100percent.com
Oceano Sea Disinfectant of
Health Pharmacy

Doxycycline Hyclate
100 mg TABS

Doxycycline Hyclate
Lot: 24000507
Exp: 01/31/2025
4286681285

Label Code
056426
H6

STI
Doxycycline Hyclate-100mg
42 Count

Doxycycline
100 mg TABS

Lot: 24000507
Exp: 01/31/2025
4286681285

Label Code
056426
H6

Doxycycline
100 mg TABS

Lot: 24000507
Exp: 01/31/2025
4286681285

Label Code
056426
H6

Doxycycline
100 mg TABS

Lot: 24000507
Exp: 01/31/2025
4286681285

Label Code
056426
H6

Doxycycline
100 mg TABS

Lot: 24000507
Exp: 01/31/2025
4286681285

Label Code
056426
H6

STI
Doxycycline-100MG
56 COUNT





DOXYCYCLINE

doxycycline capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83112-233(NDC:27808-233)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:3348955862)	DOXYCYCLINE ANHYDROUS	100 mg

Product Characteristics

Color	blue (Light Blue)	Score	no score
Shape	CAPSULE	Size	22mm
Flavor		Imprint Code	186;CY
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83112-233-28	28 in 1 BLISTER PACK; Type 0: Not a Combination Product	01/01/2025	
2	NDC:83112-233-42	42 in 1 BLISTER PACK; Type 0: Not a Combination Product	01/01/2025	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA209402	01/01/2025	

DOXYCYCLINE HYCLATE

doxycycline hyclate capsule

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83112-985(NDC:62135-985)
Route of Administration	ORAL		

Active Ingredient/Active Moiety


Ingredient Name	Basis of Strength	Strength
DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862)	DOXYCYCLINE ANHYDROUS	100 mg

Product Characteristics

Color	blue ((Light Blue))	Score	no score
Shape	CAPSULE	Size	21mm
Flavor		Imprint Code	2985
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83112-985-28	28 in 1 PACKAGE; Type 0: Not a Combination Product	09/11/1984	
2	NDC:83112-985-14	14 in 1 PACKAGE; Type 0: Not a Combination Product	09/11/1984	
3	NDC:83112-985-42	42 in 1 PACKAGE; Type 0: Not a Combination Product	09/11/1984	



Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062500	09/11/1984	

DOXYCYCLINE HYCLATE

doxycycline hyclate tablet, film coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83112-101(NDC:42806-312)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862)	DOXYCYCLINE ANHYDROUS	100 mg

Product Characteristics

Color	brown ((Beige))	Score	no score
Shape	ROUND ((Convex))	Size	9mm
Flavor		Imprint Code	312;B
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83112-101-14	14 in 1 PACKET; Type 0: Not a Combination Product	10/01/2016	12/31/2025
2	NDC:83112-101-20	20 in 1 PACKET; Type 0: Not a Combination Product	10/01/2016	12/31/2025
3	NDC:83112-101-42	42 in 1 PACKET; Type 0: Not a Combination Product	10/01/2016	12/31/2025
4	NDC:83112-101-56	56 in 1 PACKET; Type 0: Not a Combination Product	10/01/2016	12/31/2025



Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
--------------------	--	----------------------	--------------------

ANDA	ANDA062269	10/01/2016	06/30/2026
------	------------	------------	------------

DOXYCYCLINE HYCLATE

doxycycline hyclate tablet, film coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:83112-100(NDC:42806-310)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DOXYCYCLINE HYCLATE (UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862)	DOXYCYCLINE ANHYDROUS	100 mg

Product Characteristics

Color	brown ((Beige))	Score	no score
Shape	ROUND ((Convex))	Size	9mm
Flavor		Imprint Code	312;E
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:83112-100-00	14 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	
2	NDC:83112-100-14	14 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	
3	NDC:83112-100-20	20 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	
4	NDC:83112-100-28	28 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	
5	NDC:83112-100-42	42 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	
6	NDC:83112-100-56	56 in 1 PACKET; Type 0: Not a Combination Product	03/07/2025	



Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062269	03/07/2025	

Labeler - Health Department, Oklahoma State (143673015)

Revised: 12/2025

Health Department, Oklahoma State